Auris Medical is developing novel pharmaceutical products for the treatment of inner ear disorders.
We have two lead clinical-stage product candidates: Keyzilen® (AM-101), which is being developed for the treatment of acute inner ear tinnitus, and AM-111, being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA.
AM-125 is being developed for the treatment of vestibular disorders.
In addition, we are pursuing early stage projects for the treatment of tinnitus.
1) Dates of key milestones are indicative and subject to change.
ASNHL: Acute Sensorineural Hearing Loss; FPI: First Patient In.